Aastrom Biosciences Inc (NASDAQ:ASTM)

CAPS Rating: 1 out of 5

The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.

Results 1 - 18 of 18

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 8/24/2014 7:13:58 PM : Underperform Start Price: $4.15 ASTM Score: +7.59

Bioturds are like snowflakes. While they certainly all have much in common, no two are exactly alike. Aaastrom's little wrinkle is that ever since their 20:1 reverse split a year ago, the stock has been exquisitely sensitive to manipulation in the short-term. This is largely due to their low float since the split, although there are clearly other factors at work. The formerly-relevant stock blog site Seeking Alpha utilized this characteristic of the stock to their advantage, at the expense of naive retail traders. They collaborated with an "analyst" to frontrun pump articles to institutional traders for a price, then released the articles into the broad readership 24-48 hours later. Institutional traders could then sell the shares they had bought cheaply ahead of the pump to idiots chasing momentum, before the share price returned to baseline a few days later. Aastrom isn't even a consideration as a long-term investment for serious traders: it's one of the worst biopharma performers over the last five years that isn't already bankrupt.

I can't say if Aastrom has been complicit in the manipulation of their share price by external forces. However, now that Seeking Alpha has been booted into web invisibility by their unlinking from Yahoo Finance, Aastrom seems eager to fill in the gap with their own misleading PR. The price spike that facilitated my most recent red thumb came after the company issued a PR entilted "Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy". So what had Aastrom shown? Absolutely nothing. If one actually read the PR, one would see that it referred to publication of dusty old data from weak, underpowered phase II trials that had originally been released in 2012. For good measure, the data was published in a D grade journal called Circulation Research. Nevertheless, algos and momos don't read or comprehend the bodies of press releases and therefore the misleading title was good for a bump from 3.65 to 4.25 at the open. As of this writing, we're already back to 3.9 and I have little doubt that 3.5 will be seen in the near future. Aastrom is certainly selling stock into the spike, via the CEF they established with Lincoln in January that allows them to take advantage of their own manipulative PR in the cover of darkness. Examination of their recent quarterly statement reveals they raised 4M from that vehicle last quarter.

Shorting Aastrom on a PR spike is a fairly reliable way to make money. Unfortunately, shares for short-selling are hard to come by. Also, rarely and unpredictably, the price spikes can propagate for up to three days which creates some short-term pain. Nevertheless, I would have attempted to make this a rating with a real-life correlate had I not been running my watchlist at the market open on a train from York to London with a rather unreliable wireless connection. Better luck next time, hopefully.

Recs

0
Member Avatar pchop12316 (85.46) Submitted: 8/22/2014 2:42:26 PM : Underperform Start Price: $3.96 ASTM Score: +3.01

rapidly falling back into earth orbit after new facts come forward

Recs

0
Member Avatar manekatz (< 20) Submitted: 3/20/2014 10:10:09 PM : Outperform Start Price: $5.20 ASTM Score: -32.50

Great product

Recs

1
Member Avatar AndrewGreenBull (99.17) Submitted: 3/10/2014 9:38:56 AM : Outperform Start Price: $4.15 ASTM Score: -23.00

Earning will be released on Mar 13, phase 2 data of ixmyelocel-T for the treatment of dilated cardiomyopathy (DCM) probably will be released at the same time. It is due to release anytime.

http://clinicaltrials.gov/ct2/show/NCT01020968?term=ixmyelocel-T&rank=5

Institution recently endorsed with $15 million. Market cap is only around the same amount. Current price $3.32 is a steal.

I won't be surprised if ASTM pop up to $10 following positive phase 2 orphan drug data which has been in development for 5 years.

Recs

0
Member Avatar MicroMagic (< 20) Submitted: 10/5/2012 3:08:09 PM : Underperform Start Price: $31.20 ASTM Score: +125.64

I don't see how injected stem cells into someone's arteries will reduce plaque. Would someone like to explain that to me?

Recs

0
Member Avatar RikOnStilts (< 20) Submitted: 8/21/2012 3:45:27 PM : Outperform Start Price: $31.70 ASTM Score: -129.47

The use of a patient's own stem cells to remake their own cardiovascular tissue is a game changer for medical sciences. This could be a game changer for the health of many people.

Recs

0
Member Avatar flrs81 (< 20) Submitted: 5/2/2011 10:37:29 PM : Outperform Start Price: $56.40 ASTM Score: -140.76

waiting for the phase 3 results, go ASTM

Recs

0
Member Avatar sugarsugar123 (< 20) Submitted: 3/8/2011 12:05:51 PM : Outperform Start Price: $47.20 ASTM Score: -142.81

improves peoples lives with stem cells introduced into hearts making people regain their lives the heart increases its blood flow and people can walk and exercise again those peoplewho had very little chance even with heart surgery

Recs

0
Member Avatar ztur2218 (< 20) Submitted: 3/6/2011 8:58:47 AM : Outperform Start Price: $47.00 ASTM Score: -142.83

risk

Recs

0
Member Avatar captsteve66 (< 20) Submitted: 1/12/2011 9:48:25 AM : Outperform Start Price: $60.80 ASTM Score: -150.32

rated buy. cell structure is the future?

Recs

2
Member Avatar pick1998 (79.59) Submitted: 11/15/2010 5:04:23 PM : Outperform Start Price: $71.00 ASTM Score: -162.80

While I am almost 100% skeptical of Garza's pump on biomedreports.com, I do find that ASTM will have a very good chance to demonstrate historical stem cell therapy first in CLI.

The interim data (n=46) was significant. But the number of patients was small, treatment time was only 6 months.

We will see the whole data set (n=86) on Nov 18. This is a phase IIb, randomized, placebo-controlled, and double-blinded trial. Half of patients will have a treatment of 12 months. We don't have to wait too long to see the data.

If the data is significant, ASTM will triple its price. There are numerous cases in biotech that may be called "black swans".

As the recent CLI trial by Sanofi/Vical has failed, the significance of ASTM stem cell therapy will be enormous should the data be good.

Let's wait and see.

Recs

0
Member Avatar ICanFool (< 20) Submitted: 11/15/2010 4:48:20 PM : Outperform Start Price: $71.00 ASTM Score: -162.80

DCM patient(see on the webpages of ASTM) is alive and well. Motley Fools report does not recognize that. And that is Insane. Who is paying you to discredit ASTM. You guys must be out of your mind, just like Cramer!!
Read the report by Scimitar and Zacks...

Recs

1
Member Avatar platinumplay (< 20) Submitted: 7/9/2010 3:03:39 AM : Outperform Start Price: $31.40 ASTM Score: -175.03

Going to phase 3 and promising result at phase 2B. Ischemia therapy - anything that improves patient condition at this stage is an improvement over amputation.

Recs

0
Member Avatar rtrieone (< 20) Submitted: 4/9/2007 9:08:39 PM : Outperform Start Price: $244.80 ASTM Score: -145.43



They will need time to get the studies done. This stuff works and very exciting to see it all come alive and make a lot of money investing....

Recs

1
Member Avatar scott627 (< 20) Submitted: 4/8/2007 7:10:02 PM : Outperform Start Price: $257.60 ASTM Score: -145.20

Using audlt stem cells may take the edge off the whole stem cell debate. They will need to push hard the "adult" angle to come out a winner.

Recs

1
Member Avatar wynharter (< 20) Submitted: 2/23/2007 1:35:31 PM : Outperform Start Price: $240.00 ASTM Score: -145.06

Their TRC's are non-invasive, personal blood stem cells, being proven a success in clinics and create no side affects. Also non-controversal and morally acceptable.

wyn harter

Recs

0
Member Avatar verncox (< 20) Submitted: 2/14/2007 11:46:06 PM : Outperform Start Price: $243.20 ASTM Score: -144.65

Flucuates between .50 and 5.00

Recs

0
Member Avatar EXOTHERMIC (86.01) Submitted: 1/8/2007 7:22:44 PM : Outperform Start Price: $262.40 ASTM Score: -149.28

legislation is pending improving funding to stem cell research companies, expect a gain in this market at least for the short term.

Results 1 - 18 of 18

Featured Broker Partners


Advertisement